EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Computational Drug Repurposing of a Ketamine–Methylphenidate Conjugate for Targeting GLIPR1 in Human Glioma

Muzamal Hussain, Saad Karim Abbasi, Faiz Ahmad Joyia, Moin Sajjad, Noor Ul Eman, Kashaf Shafique, Nazia Kanwal, Kashif Iqbal

Futuristic Biotechnology · 31.12.2025 · 67-72

DOI: 10.54393/fbt.v5i4.220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Futuristic Biotechnology, online erschienen am 31.12.2025. Verfasst von Muzamal Hussain und 7 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gliomas are the most aggressive primary brain tumors, characterized by high mortality, therapeutic resistance, and limited treatment options due to blood–brain barrier constraints. Glioma pathogenesis-related protein 1 (GLIPR1) is highly upregulated in malignant gliomas and minimally expressed in normal brain tissue, making it a promising molecular target. Drug conjugation strategies may improve CNS delivery and therapeutic efficiency against such targets.

Objectives

This study aimed to investigate the binding potential and pharmacokinetic feasibility of a ketamine–methylphenidate conjugate against the glioma-associated protein GLIPR1 using in silico approaches. Methodology: The three-dimensional structure of GLIPR1 (PDB ID: 3Q2U) was retrieved and prepared using Discovery Studio. Structural validation was performed through Ramachandran plot analysis, SOPMA, and PROCHECK. Active site prediction was carried out using PrankWeb, and physicochemical properties were assessed with ProtParam. The ketamine–methylphenidate conjugate (SDF format) was obtained from Nouman Ali et al. and evaluated for ADMET properties using pkCSM. Molecular docking was performed using CB-Dock, and ligand–protein interactions were analyzed via Discovery Studio.

Results

Docking analysis revealed a favorable binding affinity (−6.9 kcal/mol), supported by two hydrogen bonds, five hydrophobic interactions, and one electrostatic interaction. Pharmacokinetic profiling indicated suitable absorption, moderate BBB permeability, and an acceptable safety profile, supporting CNS applicability.

Conclusions

The findings suggest that the ketamine–methylphenidate conjugate is a promising CNS-penetrant candidate with potential relevance in glioma management, warranting further experimental validation.

Zitieren

APA

Hussain, M., Abbasi, S. K., Joyia, F. A., Sajjad, M., Eman, N. U., Shafique, K., Kanwal, N., & Iqbal, K. (2025). Computational Drug Repurposing of a Ketamine–Methylphenidate Conjugate for Targeting GLIPR1 in Human Glioma. Futuristic Biotechnology, 67-72. https://doi.org/10.54393/fbt.v5i4.220

Vancouver

Hussain M, Abbasi SK, Joyia FA, Sajjad M, Eman NU, Shafique K, et al. Computational Drug Repurposing of a Ketamine–Methylphenidate Conjugate for Targeting GLIPR1 in Human Glioma. Futuristic Biotechnology. 2025:67-72. doi:10.54393/fbt.v5i4.220

BibTeX
@article{Hussain2025,
  author = {Hussain, Muzamal and Abbasi, Saad Karim and Joyia, Faiz Ahmad and Sajjad, Moin and Eman, Noor Ul and Shafique, Kashaf and Kanwal, Nazia and Iqbal, Kashif},
  title = {Computational Drug Repurposing of a Ketamine–Methylphenidate Conjugate for Targeting GLIPR1 in Human Glioma},
  journal = {Futuristic Biotechnology},
  year = {2025},
  pages = {67--72},
  doi = {10.54393/fbt.v5i4.220}
}
Kostenlos starten →